Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms

被引:896
作者
Linde, Cecilia [1 ]
Abraham, William T. [2 ,3 ]
Gold, Michael R. [4 ]
Sutton, Martin St. John [5 ]
Ghio, Stefano [6 ]
Daubert, Claude [7 ]
机构
[1] Karolinska Univ Hosp, Dept Cardiol, S-17176 Stockholm, Sweden
[2] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
[4] Med Univ S Carolina, Div Cardiol, Charleston, SC 29425 USA
[5] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA
[6] Policlin San Matteo, I-27100 Pavia, Italy
[7] CHU, Dept Cardiol, Rennes, France
关键词
cardiac resynchronization therapy; heart failure; randomized controlled trial; biventricular pacing; reverse remodeling;
D O I
10.1016/j.jacc.2008.08.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives We sought to determine the effects of cardiac resynchronization therapy (CRT) in New York Heart Association (NYHA) functional class II heart failure (HF) and NYHA functional class I (American College of Cardiology/American Heart Association stage C) patients with previous HF symptoms. Background Cardiac resynchronization therapy improves left ventricular (LV) structure and function and clinical outcomes in NYHA functional class III and IV HF with prolonged QRS. Methods Six hundred ten patients with NYHA functional class I or II heart failure with a QRS >= 120 ms and a LV ejection fraction < 40% received a CRT device (+/- defibrillator) and were randomly assigned to active CRT (CRT-ON; n=419) or control (CRT-OFF; n=191) for 12 months. The primary end point was the HF clinical composite response, which scores patients as improved, unchanged, or worsened. The prospectively powered secondary end point was LV end-systolic volume index. Hospitalization for worsening HF was evaluated in a prospective secondary analysis of health care use. Results The HF clinical composite response end point, which compared only the percent worsened, indicated 16% worsened in CRT-ON compared with 21% in CRT-OFF (p = 0.10). Patients assigned to CRT-ON experienced a greater improvement in LV end-systolic volume index (-18.4 +/- 29.5 ml/m(2) vs. -1.3 +/- 23.4 ml/m2, p < 0.0001) and other measures of LV remodeling. Time-to-first HF hospitalization was significantly delayed in CRT-ON ( hazard ratio: 0.47, p = 0.03). Conclusions The REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) trial demonstrates that CRT, in combination with optimal medical therapy (+/- defibrillator), reduces the risk for heart failure hospitalization and improves ventricular structure and function in NYHA functional class II and NYHA functional class I ( American College of Cardiology/American Heart Association stage C) patients with previous HF symptoms. ( REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction [REVERSE]; NCT00271154). (J Am Coll Cardiol 2008; 52: 1834-43) (c) 2008 by the American College of Cardiology Foundation
引用
收藏
页码:1834 / 1843
页数:10
相关论文
共 24 条
  • [1] Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure
    Abraham, WT
    Young, JB
    León, AR
    Adler, S
    Bank, AJ
    Hall, SA
    Lieberman, R
    Liem, LB
    O'Connell, JB
    Schroeder, JS
    Wheelan, KR
    [J]. CIRCULATION, 2004, 110 (18) : 2864 - 2868
  • [2] Cardiac resynchronization in chronic heart failure
    Abraham, WT
    Fisher, WG
    Smith, AL
    Delurgio, DB
    Leon, AR
    Loh, E
    Kocovic, DZ
    Packer, M
    Clavell, AL
    Hayes, DL
    Ellestad, M
    Messenger, J
    Trupp, RJ
    Underwood, J
    Pickering, F
    Truex, C
    McAtee, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (24) : 1845 - 1853
  • [4] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 225 - 237
  • [5] Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
    Bristow, MR
    Saxon, LA
    Boehmer, J
    Krueger, S
    Kass, DA
    De Marco, T
    Carson, P
    DiCarlo, L
    DeMets, D
    White, BG
    DeVries, DW
    Feldman, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2140 - 2150
  • [6] Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay.
    Cazeau, S
    Leclercq, C
    Lavergne, T
    Walker, S
    Varma, C
    Linde, C
    Garrigue, S
    Kappenberger, L
    Haywood, GA
    Santini, M
    Bailleul, C
    Daubert, JC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (12) : 873 - 880
  • [7] Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: A report from the CARE-HF study
    Cleland, J. G. F.
    Freemantle, N.
    Daubert, J-C
    Toff, W. D.
    Leisch, F.
    Tavazzi, L.
    [J]. HEART, 2008, 94 (03) : 278 - 283
  • [8] A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure - A report from the Carvedilol or Metoprolol European Trial (COMET)
    Cleland, JGF
    Charlesworth, A
    Lubsen, J
    Swedberg, K
    Remme, WJ
    Erhardt, L
    Di Lenarda, A
    Komajda, M
    Metra, M
    Torp-Pedersen, C
    Poole-Wilson, PA
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (08) : 1603 - 1611
  • [9] The effect of cardiac resynchronization on morbidity and mortality in heart failure
    Cleland, JGF
    Daubert, J
    Erdmann, E
    Freemantle, N
    Gras, D
    Kappenberger, L
    Tavazzi, L
    Cleland, JGF
    Daubert, JC
    Erdmann, E
    Gras, D
    Kappenberger, L
    Klein, W
    Tavazzi, L
    Poole-Wilson, PA
    Rydén, L
    Wedel, H
    Wellens, HJJ
    Uretsky, B
    Thygesen, K
    Böcker, D
    Marijianowski, MMH
    Freemantle, N
    Calvert, MJ
    Christ, G
    Fruhwald, F
    Hofmann, R
    Krypta, A
    Leisch, F
    Pacher, R
    Rauscha, F
    Tavernier, R
    Thomsen, PEB
    Boesgaard, S
    Eiskjær, H
    Esperen, GT
    Haarbo, J
    Hagemann, A
    Korup, E
    Moller, M
    Mortensen, P
    Sogaard, P
    Vesterlund, T
    Huikuri, H
    Niemelä, KI
    Toivonen, L
    Bauer, F
    Cohen-Solal, A
    Crocq, C
    Djiane, P
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (15) : 1539 - 1549
  • [10] Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]
    Cleland, John G. F.
    Daubert, Jean-Claude
    Erdmann, Erland
    Freemantle, Nick
    Gras, Daniel
    Kappenberger, Lukas
    Tavazzi, Luigi
    [J]. EUROPEAN HEART JOURNAL, 2006, 27 (16) : 1928 - 1932